Chronic Kidney Disease is Associated With Upper Tract Urothelial Carcinoma

A Nationwide Population-Based Cohort Study in Taiwan

Jeng-Sheng Chen, MD, Chin-Li Lu, PhD, Li-Chung Huang, MD, Cheng-Huang Shen, MD, PhD, and Solomon Chih-Cheng Chen, MD, PhD

Abstract: Increased urinary tract malignancy has been reported in end-stage renal disease (ESRD). However, little is known about chronic kidney disease (CKD). This study is designed to explore the association between CKD and upper tract urothelial carcinoma (UTUC).

Using Taiwan’s Longitudinal Health Insurance Database, we studied CKD patients between January 2000 and December 2011. The non-CKD controls were selected at a ratio of 4:1 and frequency matched by gender, age group, and index date. We used the chi-square test and t-test to analyze the sociodemographic information and comorbidities. Cox regression analysis was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).

The selected cases included 45,321 CKD cases and 181,284 controls. A significantly higher incidence of UTUC was noted in the CKD group (0.22% vs 0.07%, P < 0.001). In univariate analysis, CKD, female gender, age, hypertension, hematuria, repeated urinary tract infection, bladder cancer, and ESRD were all associated with UTUC. In multivariate analysis, only CKD, female gender, age, hematuria, bladder cancer, and ESRD were significantly associated. The HR for CKD was 1.63 (95% CI: 1.26–2.13). Females had a higher HR of 1.38 (95% CI: 1.11–1.71). After excluding those patients who progressed to dialysis or kidney transplantation, the risk for CKD was still high, with an HR of 1.72 (95% CI: 1.33–2.33).

CKD is a significant factor associated with UTUC. We should pay attention to the possibility of UTUC for CKD patients before they progress to ESRD.

INTRODUCTION

The incidence of chronic kidney disease (CKD) is an increasingly challenging problem worldwide. CKD is the predecesor of end-stage renal disease (ESRD). There is substantial evidence demonstrating higher incidence rates of urinary tract malignancy in patients with ESRD.1–4 Port et al reviewed 4,161 ESRD patients and found a 5 times the normal incidence of renal cancer.1 Two large case review studies indicated a higher incidence rate of urothelial carcinoma in Taiwanese patients with ESRD compared to the general population.2,3 Another study found that the overall adjusted hazard ratio (HR) for urinary tract cancer in ESRD patients was between 10.5 and 11.1 compared to patients without ESRD.4

Previous studies have indicated a high prevalence of CKD in upper tract urothelial carcinoma (UTUC) patients (51–58.6%).5–7 On the contrary, there are some emerging evidences for an excess risk of cancer in patients in the CKD stage.8–10 Therefore, we hypothesize that carcinogenesis may occur at the CKD stage and the association between CKD and UTUC gradually increases as CKD progresses to ESRD.

The prevalence rate of CKD in Taiwan was as high as 11.9%.11 Thus, Taiwan has a large population of CKD patients. Moreover, since Taiwan has a National Health Insurance (NHI) system with almost 100% coverage, Taiwan is an ideal study setting for exploring the association between CKD and UTUC. We postulate that it might be more representative to conduct a population-based cohort study than an institution-based study in order to elucidate the relationship between the 2 diseases. The aim of this study is to examine the association between CKD and UTUC.

MATERIALS AND METHODS

Data Source

We retrieved patient data from Taiwan’s Longitudinal Health Insurance Database (LHID2000), which was validated for its representativeness of all beneficiaries of Taiwan’s NHI in 2000. The NHI in Taiwan is a national health insurance program launched by the Taiwanese government in 1995. More than 96% of Taiwanese citizens are covered by this system.12
In LHID2000, the original claim data of 1,000,000 patients were randomly sampled from Taiwan’s National Health Insurance Research Database (NHIRD) in the year 2000. The LHID2000 provided information about both outpatient and inpatient visits. They included the diagnosis and procedure codes (coded in the International Classification of Diseases, 9th revision, Clinical Modification [ICD-9-CM]), usage of medical resources, and sociodemographic information (age, gender, residence, and insured income). The Catastrophic Illness Database (CID) in NHIRD was another data source for this study. It is a registry of all catastrophic illnesses (e.g., malignancies and long-term dialysis) bulleted by NHIRD. Patients’ medical records are submitted to an expert review board, and once the application for registration in CID is approved, the patient is exempt from any copayment for related medical services. All personal identification information in LHID2000 and CID were anonymized and encrypted. By using encrypted identification numbers, all parts of the LHID2000 and CID can be linked, allowing researchers to trace patients’ medical histories and follow their prognoses after the index date of disease. Access to NHIRD is approved by the Review Committee of the National Health Research Institute (registered number: NHIRD-101-549). This study has been approved by Institutional Review Board (IRB) of Ditmanson Chia-Yi Christian Hospital (IRB No: 104002). Because of the encryption of personal identification information, this study was remitted from full review by IRB.

**Study Subjects and Design**

The CKD and control groups were observed from January 1, 1997, to December 31, 2011, to examine the association between CKD and UTUC in Taiwan. The CKD group included all of the prevalent cases with a diagnosis of CKD (ICD-9-CM codes: 403.00, 403.10, 403.90, 404.00, 404.10, 404.11, 404.90, 404.91, 582, and 585) in LHID2000 during the study period. The date of the first diagnosis of CKD was defined as the index date. Patients were excluded if dialysis (defined as being registered in CID for dialysis) or kidney transplantation (ICD-9-CM code v42.0) or UTUC (ICD-9-CM code 1891, 1892 and being registered in CID) were recorded before their index date. The control group was randomly selected from the remaining beneficiaries of LHID2000 who had not been diagnosed with CKD, no history of dialysis, kidney transplantation, or UTUC before the year they were enrolled. The controls were frequency matched to the CKD patients by age group (±5 years) and sex in a ratio of 4:1. The index date of controls was assigned as the first date of the year they were enrolled. Both groups were followed from their index date to the date of UTUC occurrence or death, whichever came first. If the study subjects died without a prior history of UTUC during the follow-up period, their status was censored.

Comorbidities, including diabetes mellitus, hypertension, hematuria, repeated urinary tract infection (UTI), bladder cancer, and ESRD, were included. Diagnoses of these comorbidities from the year before the index date to the end of observations were all included as covariates in this study. In addition, several villages in southwestern and northeastern Taiwan, which were reported as arseniasis-endemic areas, were also identified. The urbanization level of living was classified into 4 levels according to the study by Liu et al. Chronic kidney disease (CKD) is a general term for heterogeneous disorders affecting the structure and function of the kidney. As it is an important public health issue in Taiwan, the Taiwan Society of Nephrology (TSN) launched a nationwide CKD Preventive Project in 2004. As of late 2005, the TSN adopted the simplified Modification of Diet in Renal Disease equation to calculate the estimated glomerular filtration rate. The CKD stage was classified according to the National Kidney Foundation’s Kidney Disease Outcome Quality Initiative.

According to Hwang et al, diabetes mellitus (43.2%), chronic glomerulonephritis (25.1%), hypertension (8.3%), and chronic interstitial nephritis (2.8%) are 4 major renal diseases underlying ESRD. In the definition of CKD, we included CKD (ICD-9-CM code 585), chronic glomerulonephritis (ICD-9-CM code 582), hypertensive chronic kidney disease (ICD-9-CM code 403.00, 403.10, and 403.90), and hypertensive heart and chronic kidney disease (ICD-9-CM code 404.00, 404.01, 404.10, 404.11, 404.90, and 404.91). Diabetes nephropathy is classified as ICD-9-CM code 585. We excluded ESRD patients who required dialysis. This definition encompassed most identifiable etiologies of CKD in clinical practice.

**Statistical Analysis**

We used the chi-square test and t-test to inspect the differences between the CKD and control groups in terms of all sociodemographic information and comorbidities. The chi-square test was also used to compare the differences in the cumulative incidence of kidney transplantation, dialysis, UTUC, and mortality in both groups. Univariable and multivariable Cox proportional regression analyses were used to examine the association between CKD and risk of UTUC. The adjusted HR and 95% CI were estimated after adjusting for age, gender, urbanization level, insured income, geographic area, diabetes mellitus, hypertension, hematuria, repeated UTI, bladder cancer, arseniasis-endemic areas, and ESRD. A subgroup analysis was further conducted to examine the association between pre-end-stage CKD and the risk of UTUC. In the subgroup analysis, the CKD group only included CKD patients who had not undergone dialysis or kidney transplantation during the study period. A P value of <0.05 was considered statistically significant. Data management and data analyses were performed using SAS/STAT® software, version 9.3 for Windows (SAS Institute Inc, Cary, NC).

**RESULTS**

A total of 45,321 CKD cases and 181,284 controls were analyzed in this study. There were 17,059 patients diagnosed with CKD (ICD-9-CM code 585), 18,839 patients with chronic glomerulonephritis (ICD-9-CM code 582), 2,489 patients with hypertensive chronic kidney disease (ICD-9-CM code 582), 2,934 patients with hypertensive chronic kidney disease (ICD-9-CM code 582), 2,934 patients with hypertensive kidney disease, and 4,000 patients with at least 2 above-mentioned diagnoses as shown in the supplementary Table 1, http://links.lww.com/MD/A896. More than half of the subjects were >60 years of age. Table 1 lists the sociodemographic characteristics, comorbidities, and outcomes of all included subjects. The patients in the CKD group were more likely to have a lower socioeconomic status, live in urbanized areas, live in central and southern Taiwan, and live in an arseniasis-endemic area (Table 1). Comorbidities, including diabetes mellitus, hypertension, hematuria, repeated UTI, and bladder cancer, were more prevalent in the CKD group than in the control group (all P values <0.001). In CKD group, we
TABLE 1. Sociodemographic Characteristics, Comorbidities and Outcomes for Patients with CKD and Control Group

| Variable                        | CKD Group (n = 45,321) | Control Group (n = 181,284) | P Value |
|---------------------------------|------------------------|-----------------------------|---------|
| Time for follow-ups, y (Mean ± SD) | 8.7 ± 3.4              | 9.2 ± 3.4                   | < 0.001*|
| Age, y, n (%)                  | 59.0 ± 18.4            | 58.1 ± 18.7                 | < 0.001*|
| <20                            | 1468 (3.2)             | 5872 (3.2)                  | 1.00    |
| 20–39                          | 5684 (12.5)            | 22736 (12.5)                |         |
| 40–59                          | 14292 (31.5)           | 57168 (31.5)                |         |
| 60–79                          | 18943 (41.8)           | 75772 (41.8)                |         |
| ≥80                            | 4934 (10.9)            | 19736 (10.9)                |         |
| Gender                         |                        |                             |         |
| Male                           | 23935 (52.8)           | 95740 (52.8)                | 1.00    |
| Female                         | 21386 (47.2)           | 85544 (47.2)                |         |
| Urbanization                   |                        |                             |         |
| I (Highest)                   | 12582 (27.9)           | 51738 (28.7)                | 0.01    |
| II                             | 12648 (28.0)           | 49894 (27.7)                |         |
| III                            | 7702 (17.1)            | 30673 (17.0)                |         |
| IV (Lowest)                   | 12203 (27.0)           | 48043 (26.6)                |         |
| Insured income, US$            |                        |                             |         |
| > 794                         | 6192 (13.7)            | 25938 (14.3)                | < 0.001 |
| 503–794                       | 19193 (42.4)           | 75545 (41.7)                |         |
| 0–503                         | 7441 (16.4)            | 30573 (16.9)                |         |
| 0                             | 12495 (27.6)           | 49228 (27.2)                |         |
| Geographic area                |                        |                             |         |
| North                         | 19390 (42.8)           | 83383 (46.0)                | < 0.001 |
| Central                       | 11490 (25.4)           | 42570 (23.5)                |         |
| South                         | 13101 (28.9)           | 48839 (26.9)                |         |
| East and offshore             | 1339 (3.0)             | 6490 (3.6)                  |         |
| Arsenisias-endemic area       | 363 (0.8)              | 1220 (0.7)                  | 0.003   |
| Comorbidities                 |                        |                             |         |
| Diabetes Mellitus             | 21141 (46.7)           | 44023 (24.3)                | < 0.001 |
| Hypertension                  | 33184 (73.2)           | 82039 (45.3)                | < 0.001 |
| Hematuria                     | 1367 (3.0)             | 2052 (1.1)                  | < 0.001 |
| Repeated UTI                  | 4335 (9.6)             | 6027 (3.3)                  | < 0.001 |
| Bladder cancer                | 669 (1.5)              | 988 (0.6)                   | < 0.001 |
| Outcomes of the CKD and control groups |              |                             |         |
| UTUC (%)                      | 101 (0.22)             | 124 (0.07)                  | < 0.001 |
| Dialysis (%)                  | 4816 (10.6)            | 219 (12.0)                  | < 0.001 |
| Kidney transplantation (%)    | 197 (0.43)             | 0 (0)                       | < 0.001 |
| Mortality (%)                 | 37 (0.08)              | 98 (0.05)                   | < 0.001 |

P-values were estimated by using the chi-square test, unless otherwise specified.
CKD = chronic kidney disease, USD = United Stated dollars, UTI = urinary tract infection, UTUC = upper tract urothelial carcinoma.
*Student’s t test. Exchange rate between USD$ and NT$ (New Taiwan Dollar): 31.5:1.

TABLE 2. http://links.lww.com/MD/A896. During the study period, 101 CKD patients developed UTUC, including 43 patients with bladder cancer. A significantly higher incidence of UTUC was noted in the CKD group (0.22% vs 0.07%, P < 0.001). The chronic glomerulonephritis was responsible for most UTUC cases in CKG group (please see supplementary Table 3, http://links.lww.com/MD/A896). Approximately 10.6% of the CKD patients progressed to ESRD requiring dialysis, and 0.43% received kidney transplantation. A significantly higher mortality rate was noted in the CKD group than in the non-CKD group.

**Risk Factors Associated with UTUC**

Further analysis using the Cox proportional hazard model is presented in Table 2. Using univariate analysis, we found that CKD, female gender, age, hypertension, hematuria, repeated UTI, bladder cancer, and ESRD were all associated with UTUC. In multivariate analysis, the CKD group had a 1.63-fold higher risk of UTUC than the non-CKD group after adjusting for sociodemographic characteristics and comorbidities (adjusted HR: 1.63, 95% CI: 1.26–2.13). Female gender, older age, hematuria, bladder cancer, and ESRD were associated with higher risks. Among these factors, bladder cancer had the highest hazard ratio (HR: 12.98, 95% CI: 8.97–18.78). A 1-year increase in age was associated with an elevated risk of UTUC (HR: 1.01, 95% CI: 1.00–1.02).

**Subgroup Analysis**

In the subgroup analysis, we excluded CKD patients who had progressed to dialysis or had undergone kidney transplantation during the study period. The results were calculated using multivariate analysis and are listed in Table 2. The patients in the CKD group still had an escalated risk of UTUC (HR: 1.72, 95% CI: 1.33–2.33). Sex, age, hematuria, and bladder cancer were all significantly correlated with UTUC. Interestingly, the HRs for all the aforementioned variables, except for gender, were attenuated compared with those in overall analysis. Because the bladder cancer was a well-known risk factor for UTUC, we further excluded CKD patients with history of bladder cancer and performed the multivariate analysis. We still found the risk of UTUC in these CKD patients remained significantly higher (HR: 1.84, 95% CI: 1.42–2.39).

**DISCUSSION**

This was a nationwide, population-based cohort study. During the mean follow-up period of 9.1 years, we confirmed that CKD patients had an elevated risk of UTUC compared with non-CKD patients.

Because there is well-established evidence of increased malignancy risk in ESRD and kidney transplantation patients, we excluded those CKD patients who had already progressed to ESRD or were given kidney transplantation to further elucidate the association between CKD and malignancy. After exclusion, the risk remained significantly higher (HR: 1.72, 95% CI: 1.33–2.23). As time and the underlying renal disease progress, we think the risk for UTUC may increase.

The prevalence rate of CKD in this study was lower than that in previous study,11 which identified cases from medical screening program. Many early stage CKD patients are asymptomatic and unaware to their renal diseases.16,18 Whereas the CKD cases identified in this study were those patients who already had renal symptoms or signs and searched for medical service. Though the CKD prevalence rate of this study could be underestimated, we think the association between CKD and UTUC would be more accurate.

The epidemiology of UTUC in Taiwan is quite different from that in the West. First, UTUC is a rare disease in the West and accounts for only 5% of all urothelial carcinomas,21 but
The exact etiology of this gender disparity in UTUC has not been clearly described. In Taiwan, herbal medication is prescribed to women 58.1% of the time compared to 41.9% for men. More female Chinese herbal nephropathies have been diagnosed. In the study by Chang et al, the authors report that the use of Chinese herbs, especially if they contain aristolochic acid or compound analgesics, may contribute to the development of urothelial carcinoma. A population-based study also revealed that the use of aristolochic acid-containing Chinese herbal products is associated with a dose-dependent increased risk of urinary tract cancer. We hypothesize that the discrepancy between genders in the West and the East may be due to differences in culture, lifestyle, diet, and drug use. Of course, the underlying mechanisms for gender variability in UTUC need further studies to clarify.

TABLE 2. Risk Factors Associated With the Risk of UTUC in Cox Proportional Hazard Model

| Variables                             | Overall Analysis (n = 226,605) | Subgroup Analysis* (n = 221,532) |
|---------------------------------------|--------------------------------|----------------------------------|
|                                       | cHR (95% CI)                  | aHR (95% CI)                     | aHR (95% CI)                     |
| Group                                 |                                |                                 |                                 |
| CKD                                   | 2.61 (2.11–3.23)               | 1.63 (1.26–2.13)                 | 1.72 (1.33–2.23)                 |
| Control                               | Ref.                           | Ref.                             | Ref.                            |
| Gender                                |                                |                                 |                                 |
| Female                                | 1.25 (1.02–1.62)               | 1.38 (1.11–1.71)                 | 1.35 (1.08–1.72)                 |
| Male                                  | Ref.                           | Ref.                             | Ref.                            |
| Age, per 1 year increase              | 1.01 (1.01–1.02)               | 1.01 (1.00–1.02)                 | 1.01 (1.00–1.02)                 |
| Urbanization level of residence       |                                |                                 |                                 |
| I (Highest)                           | 0.92 (0.67–1.22)               | 0.96 (0.68–1.35)                 | 0.95 (0.66–1.38)                 |
| II                                    | 1.07 (0.81–1.40)               | 1.07 (0.79–1.46)                 | 0.99 (0.71–1.39)                 |
| III                                   | 0.84 (0.60–1.18)               | 0.88 (0.62–1.26)                 | 0.94 (0.64–1.36)                 |
| IV (Lowest)                           | Ref.                           | Ref.                             | Ref.                            |
| Monthly insured income, USD           |                                |                                 |                                 |
| > 794                                 | 0.85 (0.60–1.20)               | 1.10 (0.76–1.59)                 | 1.16 (0.78–1.72)                 |
| >503–794                              | 0.87 (0.67–1.12)               | 0.91 (0.69–1.18)                 | 0.85 (0.63–1.15)                 |
| >0–503                                | 1.06 (0.79–1.44)               | 1.15 (0.85–1.57)                 | 1.24 (0.89–1.72)                 |
| 0                                     | Ref.                           | Ref.                             | Ref.                            |
| Geographic area of residence          |                                |                                 |                                 |
| Northern                              | 0.83 (0.46–1.49)               | 0.82 (0.44–1.53)                 | 0.81 (0.42–1.56)                 |
| Central                               | 0.79 (0.43–1.46)               | 0.77 (0.42–1.42)                 | 0.79 (0.42–1.51)                 |
| Southern                              | 1.11 (0.61–2.00)               | 1.03 (0.56–1.89)                 | 0.97 (0.51–1.84)                 |
| Eastern                               | Ref.                           | Ref.                             | Ref.                            |
| Diabetes                              | 1.21 (0.98–1.51)               | 0.87 (0.69–1.10)                 | 0.94 (0.72–1.22)                 |
| Hypertension                          | 1.47 (1.19–1.82)               | 0.91 (0.71–1.16)                 | 0.98 (0.76–1.27)                 |
| Hematuria                             | 10.14 (7.52–13.67)             | 2.13 (1.43–3.17)                 | 2.20 (1.37–3.52)                 |
| Repeated UTI                          | 2.20 (1.57–3.09)               | 1.27 (0.89–1.80)                 | 1.27 (0.84–1.92)                 |
| Bladder cancer                        | 28.57 (21.83–37.38)            | 12.98 (8.97–18.78)               | 12.30 (7.97–18.98)               |
| Arseniasis-endemic area               | 2.03 (0.84–4.90)               | 1.70 (0.68–4.21)                 | 2.13 (0.85–5.34)                 |
| ESRD                                  | 7.80 (5.85–10.40)              | 3.38 (2.38–4.81)                 | Not included                     |

Death from other causes led to censorship of data.
Exchange rate of New Taiwan Dollar: USD = 31.5: 1.

aHR = adjusted hazard ratio, cHR = crude hazard ratio, CI = confidence interval, CKD = chronic kidney disease, ESRD = end-stage renal disease, Ref. = reference group, USD = United States dollars, UTI = urinary tract infection, UTUC = upper tract urothelial carcinoma.

*Exclude patients with dialysis or kidney transplantation.

UTUC occurrence in Taiwan is as high as 31% of all urothelial carcinomas. Second, the male-to-female ratio (M/F ratio) of UTUC is between 2:1 and 4:1 in the West, but the M/F ratio is 1:1.3 in Taiwan. Although there were fewer females than males with CKD in this study (47.2% vs 52.8%, Table 1), female CKD patients had a significantly higher risk for UTUC (Table 2). The finding of females with a higher risk for UTUC in accordance with previous investigations conducted in the East.

CKD is associated with an increased risk of bladder cancer recurrence in patients with UTUC who have been treated by nephroureterectomy. In addition, the aggressiveness of UTUC increases with the severity of CKD. This study also found that CKD patients with bladder cancer had a 13-fold higher risk of UTUC (Table 2). In subgroup analysis, the risk remained significantly higher (P < 0.001 in Table 2). In addition, we found that the risk of UTUC was 1.8-fold in CKD patients without bladder cancer. We may suggest there is an interaction between CKD and urothelial carcinoma and they may share similar risk factors.

Hung et al have demonstrated an association between CKD severity and UTUC aggressiveness. Though the risk for UTUC in CKD patients was only 0.22% in this present study, it was 3 times higher than that in non-CKD patients. Therefore, preventing CKD progression is still an important issue, because it may also decrease the risk of UTUC.

In our study, aging, male gender, and lower socioeconomic status were associated with CKD, which is in agreement with previous studies. We found that most CKD patients lived in urbanized areas. CKD patients require more medical care. In urbanized areas, there are more medical resources, which may explain the concentration of CKD patients in these areas. Increased levels of hematuria and repeated UTIs were noted.
National Health Insurance Research Database (NHIRD). In our study, the diagnosis of CKD and UTUC was based on the ICD-9-CM codes. Therefore, the association between CKD and UTUC in our study could be negatively affected. This is a common methodological limitation when using administrative databases. We would recommend further studies to investigate these potential confounding factors. Third, we included prevalent cases with the diagnosis of CKD but not newly diagnosed cases. Therefore, it was unable to estimate the possible onset of UTUC among CKD patients. Fourth, the diagnosis of CKD and other comorbidities were based on ICD-9-CM codes. Many previous population-based studies used ICD-9-CM codes have validated this approach. In Taiwan, the NH Bureau regularly scrutinized the charts and audited the medical charges to prevent malpractices and inadequate medical expenses. Misclassification was possible, but was most likely to be minimal.

CONCLUSIONS

This was a large-scale and long-term follow-up study. We demonstrated that CKD patients have an elevated risk for UTUC compared with non-CKD patients. Excluding CKD patients who had progressed to dialysis or underwent kidney transplantation, the risk remained high. Female CKD patients had a significantly higher risk for UTUC. In addition to ESRD patients, CKD patients should also be carefully monitored for UTUC, especially patients presenting with hematuria.

REFERENCES

1. Port FK, Ragheb NE, Schwartz AG, et al. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis. 1989;14:119–123.
2. Wang TY, Hu CJ, Kuo CW, et al. High incidence and recurrence of transitional cell carcinoma in Taiwanese patients with end-stage renal disease. Nephrology. 2011;16:225–231.
3. Ou JH, Pan CC, Lin JS, et al. Transitional cell carcinoma in dialysis patients. Eur Urol. 2000;37:90–94.
4. Liang J-A, Sun L-M, Yeh J-J, et al. The association between malignancy and end-stage renal disease in Taiwan. Jap J Clin Oncol. 2011;41:752–757.
5. Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer. 2010;116:2967–2973.
6. Kaag MG, O’Malley RL, O’Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58:581–587.
7. Xiong G, Chen X, Li X, et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc. 2014;113:521–526.
8. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010;23:253.
9. Christensen S, Savage C, Sjoberg DD, et al. Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer. 2015;133:1452–1458.
10. Jorgensen L, Heuch I, Jenssen T, et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008;19:992–998.
11. Wen CP, Cheng TYD, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–2182.
12. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Nat Cancer Inst. 2010;102:179–186.
13. Tan LB, Chen KT, Guo HR. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. BJU Int. 2008;102:48–54.
14. Chou HY, Chou ST, Hsu YH, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol. 2001;153:411–418.
15. Liu C-Y, Hung Y, Chuang Y, et al. Incorporating development stratification of Taiwan townships into sampling design of large-scale health interview survey. J Health Manag. 2006;4:1–22.
16. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180.
17. Taiwan Society of Nephrology: History of prevention of chronic kidney disease in Taiwan. Available at: http://www.tsn.org.tw/UI/H/H00202.aspx (accessed March 31, 2015).
18. Hsu CC, Hwang SJ, Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis. 2006;48:727–738.
19. Eknayan G, Levin N, et al. K/DOQI clinical practice guidelines for chronic kidney disease in China: a 10-year study of moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer. 2015;133:1452–1458.
20. Watanabe A, Sato M, Yamagami T, et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc. 2014;113:521–526.
21. Williams CB, Mitchell JP. Carcinoma of the ureter—a review of 54 cases. Br J Urol. 1973;45:377–387.
22. Yang MH, Chen KK, Yen CC, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urol. 2002;59:681–687.
23. Babaian RJ, Johnson DE. Primary carcinoma of the ureter. J Urol. 1980;123:357–359.
24. Ouzanne A, Roupret M, Leon P, et al. [Epidemiology and risk factors of upper urinary tract tumors: literature review for the yearly scientific report of the French National Association of Urology]. Progres Urologie. 2014;24:966–976.
25. Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. *Cancer*. 1999;85:1342–1344.

26. Hung PH, Shen CH, Tsai HB, et al. Gender effect on renal outcome in patients with urothelial carcinoma. *World J Urol.* 2011;29:511–516.

27. Wang J. Establishment of an active surveillance system for Chinese herbal medicine. *Yearbook Chin Med Pharm.* 2006;24:157–280.

28. Wu FL, Chen YM, Lai TS, et al. Does Chinese herb nephropathy account for the high incidence of end-stage renal disease in Taiwan? *Nephron Clin Pract.* 2012;120:c215–c222.

29. Chang CH, Yang CM, Yang AH. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. *Cancer.* 2007;109:1487–1492.

30. Chung SD, Huang KH, Lai MK, et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. *Am J Kidney Dis.* 2007;50:743–753.

31. Hung PH, Shen CH, Chiu YL, et al. The aggressiveness of urinary tract urothelial carcinoma increases with the severity of chronic kidney disease. *BJU Int.* 2009;104:1471–1474.

32. Evans PD, Taal MW. Epidemiology and causes of chronic kidney disease. *Medicine.* 2015;43:450–453.

33. Vejakama P, Ingsathit A, Attia J, et al. Epidemiological study of chronic kidney disease progression: a large-scale population-based cohort study. *Medicine.* 2015;94:e475.

34. Chiou JM, Wang SL, Chen CJ, et al. Arsenic ingestion and increased microvascular disease risk: observations from the south-western arseniasis-endemic area in Taiwan. *Int J Epidemiol.* 2005;34:936–943.

35. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiological features of CKD in Taiwan. *Am J Kidney Dis.* 2007;49:46–55.

36. Chen YC, Lin HY, Li CY, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. *Kidney Int.* 2014;85:1200–1207.